Abstract
Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Current Pharmaceutical Biotechnology
Title:Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Volume: 17 Issue: 7
Author(s): Radzislaw Mierzynski, Dominik Dluski, Dorota Darmochwal-Kolarz, Elzbieta Poniedziałek-Czajkowska, Bozena Leszczynska-Gorzelak, Zaneta Kimber-Trojnar, Agnieszka-Wankowicz and Jan Oleszczuk
Affiliation:
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Abstract: Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Export Options
About this article
Cite this article as:
Mierzynski Radzislaw, Dluski Dominik, Darmochwal-Kolarz Dorota, Poniedziałek-Czajkowska Elzbieta, Leszczynska-Gorzelak Bozena, Kimber-Trojnar Zaneta, Agnieszka-Wankowicz and Oleszczuk Jan, Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301104323
DOI https://dx.doi.org/10.2174/1389201017666160301104323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural and Nanotechnology Based Treatment: An Alternative Approach to Psoriasis
Current Nanomedicine A Review of the Effects of Gold, Silver, Selenium, and Zinc Nanoparticles on Diabetes Mellitus in Murine Models
Mini-Reviews in Medicinal Chemistry P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery Genetic Variability of Matrix Metalloproteinase Genes in Cardiovascular Disease
Current Topics in Medicinal Chemistry The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Cardiovascular Effects of Metabolic Surgery on Type 2 Diabetes
Current Cardiology Reviews Lifestyle Interventions for Cardiovascular Risk Reduction in Women with Breast Cancer
Current Cardiology Reviews Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Insulin Resistance in Brain and Possible Therapeutic Approaches
Current Vascular Pharmacology Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry Aldose Reductase Inhibitory Potential of Several Thiazolyl-thiazolidine- 2,4-Diones
Letters in Drug Design & Discovery Melanocortin - 4 Receptor Agonists for the Treatment of Obesity
Current Topics in Medicinal Chemistry Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia
Current Medicinal Chemistry Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Ubisol-AquaTM: Coenzyme Q10 Prevents Antiretroviral Toxic Neuropathy in an In Vitro Model
Current HIV Research Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Current Medicinal Chemistry Effects of Renin-Angiotensin-Aldosterone System Blockade on Diabetic Patients
Current Enzyme Inhibition